Navigation Links
Pitt develops biodegradable artery graft to enhance bypass surgeries
Date:6/24/2012

PITTSBURGHWith the University of Pittsburgh's development of a cell-free, biodegradable artery graft comes a potentially transformative change in coronary artery bypass surgeries: Within 90 days after surgery, the patient will have a regenerated artery with no trace of synthetic graft materials left in the body.

Research published online June 24 in Nature Medicine highlights work led by principal investigator Yadong Wang, a professor in Pitt's Swanson School of Engineering and School of Medicine's Department of Surgery, who designed grafts that fully harness the body's regenerative capacity. This new approach is a philosophical shift from the predominant cell-centered approaches in tissue engineering of blood vessels.

"The host site, the artery in this case, is an excellent source of cells and provides a very efficient growth environment," said Wang. "This is what inspired us to skip the cell culture altogether and create these cell-free synthetic grafts."

Wang and fellow researchers, Wei Wu, a former Pitt postdoctoral associate (now a postdoctoral associate at Yale University), and Robert Allen, a PhD student in bioengineering, designed the graft with three properties in mind. First, they chose a graft materialan elastic polymer called PGSthat is resorbed quickly by the body. Then, they examined graft porosity and selected parameters that allow immediate cell infiltration. Wang's team borrowed a procedure developed by another team of Pitt researchersDavid Vorp, professor of bioengineering and surgery, and William R. Wagner, interim director of the University's McGowan Institute for Regenerative Medicine and a Pitt professor of surgery, bioengineering, and chemical engineeringwrapping the vascular graft with a fibrous sheath to trap the cells. Finally, Wang and his fellow researchers wanted a coating for the grafts that would reduces blood clotting and bind many growth factors, so they used heparin, a molecule that does just that.

"The results were porous grafts that are suturable," said Wang. "And the rapid remodeling of the grafts led to strong and compliant new arteries. The extent of the changes in the grafts that occurred in just 90 days was remarkable."

Wang and his colleagues made grafts as small as 1 mm in diameter and monitored the graft's transformation in vivo for three months. Because the graft was highly porous, cells were easily able to penetrate the graft wall, and mononuclear cells occupied many of the pores within three days. Within 14 days, smooth muscle cellsan important blood vessel builderappeared. At 28 days, cells were distributed more evenly throughout the graft. At 90 days, most inflammatory cells were gone, which correlated with the disappearance of the graft materials. The artery was regenerated in situ and pulsed in sync with the host. Furthermore, the composition and properties of the new arteries are nearly the same as native arteries.

"This report is the first that shows a nearly complete transformation of a synthetic plastic tube to a new host artery with excellent integration within three months," said Wang. "Most likely, the amount of time it takes to regenerate an artery can be further shortened as we refine the system."

Current approaches toward tissue-engineered arteries require a long production cycle because of the required cell culture steps. The newly developed graft is made in a few days, stores in a dry pouch at ambient temperature, and is readily available off the shelf. The ease of use and storage are similar to the conventional Dacron grafts.


'/>"/>

Contact: B. Rose Huber
rhuber@pitt.edu
412-624-4356
University of Pittsburgh
Source:Eurekalert

Related biology news :

1. MindSpec develops Autism Quiz app
2. Geneticist develops tool to identify genes important in disease, tailoring individual treatment
3. Pod corn develops leaves in the inflorescences
4. Genetic research develops tools for studying diseases, improving regenerative treatment
5. Diabetes Research Institute develops oxygen-generating biomaterial
6. Biodegradable transistors -- made from us
7. Fat outside of arteries may influence onset of coronary artery disease
8. New discovery may lead to effective prevention and treatment of graft-versus-host dsease
9. Resveratrol may be a natural exercise performance enhancer: U of A medical research
10. JRC and US NOAA enhance cooperation on climate, weather, oceans and coasts
11. ASBMB wins National Science Foundation grant to enhance K-12 science education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... LINDA, CA (PRWEB) , ... October 11, 2017 ... ... to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding ... (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM ... firm for the life sciences and healthcare industries, announces a presentation by Subbu ... , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a ...
Breaking Biology Technology: